Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-amoxicillin versus lansoprazole-amoxicillin dual therapy for treatment-resistant Helicobacter pylori
IRCT20251010067573N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan, lansoprazole and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Nov 2025; status: completed.
02
Drugs
vonoprazanlansoprazoleamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20251010067573N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251010067573N1.